MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

TY - JOUR

T1 - MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

AU - Comi, Giancarlo

AU - Cook, Stuart D

AU - Giovannoni, Gavin

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Sørensen, Per Soelberg

AU - Vermersch, Patrick

AU - Hamlett, Anthony C

AU - Viglietta, Vissia

AU - Greenberg, Steven J

PY - 2013/4

Y1 - 2013/4

N2 - We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p 

AB - We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p 

U2 - 10.1007/s00415-012-6775-0

DO - 10.1007/s00415-012-6775-0

M3 - Journal article

C2 - 23263473

SN - 0939-1517

JO - Deutsche Zeitschrift fur Nervenheilkunde

JF - Deutsche Zeitschrift fur Nervenheilkunde

ER -